Accessibility Menu
Arrow-Thin-Down
S&P 500
6,672.57
-1.5%
-103.23
Arrow-Thin-Down
DJI
46,677.85
-1.6%
-739.42
Arrow-Thin-Down
NASDAQ
22,311.98
-1.8%
-404.16
Arrow-Thin-Down
Bitcoin
$70,423.00
-0.4%
-$268.68
Arrow-Thin-Down
AMZN
$209.42
-1.5%
-$3.23
Arrow-Thin-Down
GOOG
$303.23
-1.7%
-$5.19
Arrow-Thin-Down
META
$638.34
-2.5%
-$16.52
Arrow-Thin-Down
MSFT
$401.93
-0.7%
-$2.95
Arrow-Thin-Down
NVDA
$183.18
-1.5%
-$2.85
Arrow-Thin-Down
TSLA
$395.69
-3.0%
-$12.13
Most Active StocksDaily Stock GainersDaily Stock Losers

Down but Not Out: Is Novo Nordisk a Conditional Buy as Eli Lilly Leads the GLP‑1 Market?

Novo Nordisk looks cheap, but a rebound hinges on fixing execution and management credibility.

By Motley Fool YouTube – Mar 6, 2026 at 6:05PM EST

Key Points

  • Novo Nordisk shares look cheap, but execution and management changes weigh on investor confidence.
  • Eli Lilly’s stronger GLP-1 growth and consistency support its premium versus Novo’s conditional value story.

Is Novo Nordisk (NVO 1.91%) a bargain or a value trap as it battles Eli Lilly (LLY 2.21%) for GLP‑1 leadership, execution credibility, and premium growth? Watch the video below to see how investors might navigate this high‑stakes rivalry.

*This video was published on Feb. 24, 2026.

Read Next

Stocks Mentioned

Novo Nordisk Stock Quote
Novo Nordisk
NYSE: NVO
$38.05
(-2.01%)-$0.78
Eli Lilly Stock Quote
Eli Lilly
NYSE: LLY
$977.76
(-2.21%)-$22.08

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services